Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business \
11 min read
\
\

Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business

30-Nov-2022
Bengaluru (Karnataka) [India], November 30 (ANI/PRNewswire): Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
30-Nov-2022 Business
\